Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Because PAH can be severe and often challenging to treat, it can lead to severe short- and long-term health challenges. Read on to learn more about the medications available to treat PAH ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

the FDA-recommended dose for treatment of PAH is 40 mg daily. While not numerous, more pharmacogenetic studies exist in PDE5 inhibitors than in other PH medications and almost exclusively in ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...

PAH is a life-threatening disease, caused by the narrowing of blood vessels in the lungs, which is currently treated mainly with drugs that dilate the blood vessels, like endothelin antagonists ...

It was founded in 2015 and develops therapies for pulmonary hypertension [PH]. Currently, GOSS’ leading drug is Seralutinib, previously called GB002, a tyrosine kinase inhibitor for PH.

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Of these groups, pulmonary arterial hypertension (PAH) is the most studied and, therefore, all of the currently available drug classes (prostacyclin analogs, endothelin receptor antagonists and ...